|
Match
|
Document |
Document Title |
|
|
7427685 |
Therapeutic substituted cyclopentanes
Therapeutic compounds according to one of the structures below are disclosed herein.
|
|
|
7425534 |
Compositions and methods for modulating muscle cell and tissue contractility
The present invention relates to compositions and methods comprising one or more domains of urokinase-type plasminogen activator (uPA) in an amount effective to modulate one or more of the...
|
|
|
7423177 |
Carboxamide derivatives as therapeutic agents
This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of...
|
|
|
7420055 |
Aryl sulfonamides
Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9....
|
|
|
7413866 |
Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
The present invention provides methods for identifying an agent that specifically binds and/or modulates one topology of a chemokine receptor but not a second topology of the receptor. Such agents...
|
|
|
EP1950206A1 |
Benzoxazocines and their use as monoamine-reuptake inhibitors
A compound of the general formula (1):
wherein one of W, X, Y and Z is N or CR 4 and the others are each CH;
and R 4 is a specified substituent. These compounds inhibit monoamine reuptake, and...
|
|
|
7378438 |
Beta-agonist compounds comprising nitric oxide donor groups and reactive oxygen species scavenger groups and their use in the treatment of respiratory disorders
The present invention relates to multifunctional β-agonist compounds comprising a reactive oxygen species scavenger group and a nitric oxide donor, and their use for the treatment of respiratory...
|
|
|
7378111 |
Regulation of GSK-3α activity for the treatment or prevention of Alzheimer's disease
Provided is a novel use of therapeutic concentrations of an inhibitor of glycogen synthase kinase-3 (GSK-3), including lithium or any other GSK-3 inhibitor, to block, reduce or inhibit processing...
|
|
|
7374891 |
Methods to identify compounds that modulate rage
Provided are methods to detect of modulators of the Receptor for Advanced Glycated Endproducts (RAGE). The invention comprises a method for detection of RAGE modulators comprising: adsorbing a RAGE...
|
|
|
EP1920782A1 |
Carboyhdrate specific cellular immunity inducing microorganisms and fractions thereof
The present invention relates to the field of prevention and treatment of disorders associated with the occurrence of certain carbohydrate epitopes. More particularly, the present invention relates...
|
|
|
EP1920781A1 |
Compositions comprising a core-1 positive microorganism and their use for the treatment or prophylaxis of tumors
The present invention relates to the field of prevention and treatment of gastrointestinal disorders. More particularly, the present invention relates to the prevention and treatment of...
|
|
|
7371846 |
CD4-independent HIV envelope proteins as vaccines and therapeutics
The invention relates to novel CD4-independent HIV Envelope proteins and uses therefor.
|
|
|
7361678 |
Azole derivatives and fused bicyclic azole derivatives as therapeutic agents
This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of...
|
|
|
7358229 |
Deuterated cyclosporin analogs and their use as immunomodulating agents
Cyclosporine derivatives are disclosed which possess enhanced efficacy and reduced toxicity over naturally occurring and other presently known cyclosporins and cyclosporine derivatives. The...
|
|
|
7335653 |
Bis-aryl sulfonamides
Compounds are provided that act as potent antagonists of chemokine receptors. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the...
|
|
|
7332472 |
Cyclosporine analogue mixtures and their use as immunomodulating agents
The invention is directed to isomeric mixtures of cyclosporine analogues that are structurally similar to cyclosporine A. The mixtures possess enhanced efficacy and reduced toxicity over the...
|
|
|
7329684 |
Benzimidazole derivatives as therapeutic agents
This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of...
|
|
|
7326698 |
Prostaglandin analogs
Compounds comprising
or a pharmaceutically acceptable salt or a prodrug thereof is disclosed herein. A, X, J, and E are as described herein. These compounds are useful for treating diseases.
|
|
|
7323477 |
7-((1H-imidazol-4-yl)methyl)-5,6,7,8-tetrahydroquinoline
A compound having a structure
or a pharmaceutically acceptable salt, or a prodrug thereof is disclosed herein. Therapeutic methods, compositions, and medicaments related thereto are also...
|
|
|
EP1878721A1 |
4-Piperidylbenzamides as 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors
A novel class of compounds of the general formula (I), their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are...
|
|
|
EP1875909A2 |
Use of antagonists of PYY receptors for treating irritable bowel syndrome
The present invention concerns the use of antagonists of peptide YY receptors for treating irritable bowel syndrome (IBS) in a human subject. The antagonists may be used in conjunction with...
|
|
|
EP1862181A2 |
Combination therapy using an 11B-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders
Combination therapy comprising the administration of an 11β-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent useful for treating, preventing and reducing the risk of...
|
|
|
7300932 |
Pyrrolo[1,2-b]pyridazine derivatives
Compounds, pharmaceutical compositions and methods that are useful in the treatment or prevention of metabolic and cell proliferative diseases or conditions are provided herein. In particular, the...
|
|
|
EP1854487A2 |
Combinations of an 11-beta-hydroxysteroid dehaydrogenase type 1 inhibitor and a glucocorticoid receptor agonist
Combination therapy comprising the administration of an 11β-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist for treating some forms of cancer, diseases and...
|
|
|
7294472 |
Method for identifying modulators of G protein coupled receptor signaling
This invention relates to methods for identifying peptides and other compounds which block or enhance G protein coupled receptor mediated signaling with high affinity and specificity and/or which...
|
|
|
7282489 |
Compositions and methods for performing reverse gene therapy
The invention relates to compositions and methods for reverse gene therapy, wherein a gene therapy vector encoding a gene product (e.g. a protein) which is usually only expressed in cells of an...
|
|
|
EP1816138A1 |
Cyclosporine analogue mixtures and their use as immunomodulating agents
The invention is directed to isomeric mixtures of cyclosporine analogues that are structurally similar to cyclosporine A . The mixtures possess enhanced efficacy and reduced toxicity over the...
|
|
|
7253007 |
Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
Ligands of CCX-CKR2 and the biological role of CCX-CKR2 in cancer is described.
|
|
|
7247611 |
Compositions and methods for promoting internalization and degradation of urokinase-type plasminogen activator
The invention includes compositions and methods for promoting internalization and degradation of urokinase-type plasminogen activator.
|
|
|
EP1808177A2 |
Methods of treatment of mitochondrial disorders
In accordance with the present invention, there are provided methods for the treatment of mitochondrial disorders. Invention methods include the administration of a pyrimidine-based nucleoside such...
|
|
|
EP1808168A1 |
Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level
The present invention concerns combination of an amount of a GPR1 19 agonist with an amount of a dipeptidyl peptidase IV (DPP-IV) inhibitor such that the combination provides an effect in lowering...
|
|
|
7244727 |
Fused bicyclic nitrogen-containing heterocycles
Compounds, pharmaceutical compositions and methods that are useful in the treatment or prevention of metabolic and cell proliferative diseases or conditions are provided herein. In particular, the...
|
|
|
7244412 |
Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia
Disclosed is a method of manipulating the rate of upper gastrointestinal transit of a substance in a mammal. Also disclosed are methods of manipulating satiety and post-prandial visceral blood...
|
|
|
EP1798223A2 |
Aryl Sulfonamides
Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9....
|
|
|
7227035 |
Bis-aryl sulfonamides
Compounds are provided that act as potent antagonists of chemokine receptors. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the...
|
|
|
EP1787982A2 |
11Beta-Hydroxysteroid dehydrogenase type 1 active compounds
A novel class of compounds of the general formula (I), their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are...
|
|
|
EP1785424A2 |
Fused 1,2,4-triazoles and pharmaceutical uses thereof
The use of fused 1,2,4-triazoles for modulating the activity of 11 β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and the use of these compounds as pharmaceutical compositions has been...
|
|
|
EP1782859A2 |
Pharmaceutical use of substituted pyrazolo [1,5- a]pyrimidines
The use of substituted pyrazolo[1,5- a ]pyrimidines for modulating the activity of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and the use of these compounds as pharmaceutical compositions...
|
|
|
EP1782823A2 |
IL-21 peptides and nucleic acids
The invention relates to an IL-21 polypeptide having the sequence of residues 30-162 of IL-21 and nucleic acid encoding such polypeptides.
Also disclosed is the formulation of pharmaceutical...
|
|
|
7214482 |
Steroid-activated nuclear receptors and uses therefor
A novel nuclear receptor, termed the steroid and xenobiotic receptor (SXR), a broad-specificity sensing receptor that is a novel branch of the nuclear receptor superfamily, has been discovered. SXR...
|
|
|
7208279 |
Method for identifying inhibitors of G protein coupled receptor signaling
This invention relates to methods for identifying peptides and other compounds which block G protein coupled receptor mediated signaling with high affinity and specificity. Assays developed in...
|
|
|
7183324 |
2,3,4-substituted cyclopentanones as therapeutic agents
Disclosed herein are compounds comprising
or a pharmaceutically acceptable salt or a prodrug thereof;
wherein Y, A, B, J, and E are further described.
Methods, compositions, and medicaments...
|
|
|
7183310 |
Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
A compound comprising
or a pharmaceutically acceptable salt or a prodrug thereof, having the groups described in detail herein is disclosed.
Also disclosed herein are compounds comprising
...
|
|
|
7169807 |
10-Hydroxy-11-dihydroprostaglandin analogs as selective EP4 agonists
A compound comprising
or a pharmaceutically acceptable salt or a prodrug thereof,
wherein the dashed line represents the presence or absence of a double bond; J is C═O or CHOH; A is —(CH 2...
|
|
|
EP1743891A1 |
Heterocyclic compounds and methods for modulating CXCR3 function
Compounds and compositions are provided that bind the CXCR3 chemokine receptor and which are useful for treating diseases associated with CXCR3 activity, such as multiple sclerosis.
|
|
|
7160694 |
Nucleic acids encoding TANGO405 and functional fragments and uses thereof
The invention provides isolated nucleic acids encoding a variety of proteins having diagnostic, preventive, therapeutic, and other uses. These nucleic and proteins are useful for diagnosis,...
|
|
|
7157464 |
Substituted piperazines
Compounds are provided that act as potent antagonists of the CCR1 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR1....
|
|
|
7141648 |
Synthesis of cyclosporin analogs
The invention is directed to isomeric mixtures of cyclosporine analogues that are structurally similar to cyclosporine A. The mixtures possess enhanced efficacy and reduced toxicity over the...
|
|
|
7141417 |
Compositions, kits, and methods relating to the human FEZ1 gene, a novel tumor suppressor gene
The invention relates to isolated polynucleotides homologous with a portion of one strand of the human tumor suppressor gene, FEZ1, and to the tumor suppressor protein encoded thereby, Fez1. The...
|
|
|
EP1721615A1 |
Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis
The present application relates to pharmaceutical compositions and methods for treatment of urogenital diseases and bone metastasis in a human, which pharmaceutical composition contains an...
|